GVR Report cover Women's Health Diagnostics Market Size, Share & Trends Report

Women's Health Diagnostics Market Size, Share & Trends Analysis Report By End Use, By Application (Cancer, Infectious Disease, Osteoporosis, Pregnancy, Prenatal), and Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-581-6
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Industry Insights

The global women’s health diagnostics market size was valued at around USD 16.5 billion in 2017. It is expected to expand at a CAGR of 6.9% during the forecast period. Rising prevalence of infectious diseases, such as hepatitis and urinary tract infection, among women is anticipated to drive the market during the forecast period.

Early detection of any health issue with help of digital and mobile mammography, such as breast MRI, ultrasound, and bone density testing, is critical. Advancements in medical science offer lucrative opportunities to keep a check on women-centric conditions that include infectious diseases, osteoporosis, and breast cancer. This is estimated to work in favor of the market. According to data published by National Center for Biotechnology Information (NCBI), women are 30.0% more prone to be infected with HIV compared to men.

U.S. women’s health diagnostics market

According to National Institutes of Health (NIH), 40.0% of women contract at least one UTI in their lifetime. It also states that women aged under 50 years are 30 times likelier than men to develop a UTI. In the U.S., women suffering from UTIs register 8.1 million visits to healthcare providers each year.

Furthermore, product launches, expansion, mergers & acquisitions, and certain government initiatives are projected to boost the growth of the market during the forecast period. For instance, in February 2014, Roche launched a fully automated CINtec PLUS cytology test, a new test for screening of cervical cancer that improves detection and early intervention of precancerous cervical disease.

Application Insights

The market, on the basis of application, has been segmented into cancer testing, infectious disease testing, osteoporosis testing, pregnancy & fertility testing, and prenatal testing. Cancer dominated the market in 2017 due to introduction of technologically advanced hybrid imaging instruments with enhanced accuracy. For instance, in July 2017, Quest Diagnostics acquired Med Fusion and Clear Point laboratories in Texas to expand its laboratory business for diagnosis of cancer among women.

Various collaborations among key players, governments, and other agencies to enhance accessibility of patients to diagnostics of various diseases are poised to bolster the growth of the market. For instance, in November 2017, BGI and Lunenfeld-Tanenbaum Research Institute signed a collaborative agreement to develop a genomics-based diagnostic test for early identification of women susceptible to preterm birth and other pregnancy complications.

In 2015, UNITAID and Population Services International started implementing self-testing through four-year Self-Testing Africa Research (STAR) project. The STAR project distributed 750,000 self-test kits from 2015 to 2017 across three countries, namely Zambia, Malawi, and Zimbabwe.

End Use Insights

Hospitals and diagnostics centers accounted for the largest share in the women’s health diagnostics market in 2017. The segment is expected to maintain its position in the market through 2025 as they are usually the first choice of patients to visit for detection of cancer, infectious diseases, and osteoporosis, among others.

The home segment is anticipated to observe lucrative growth during the forecast period owing to increasing investments by market players to commercialize portable and point of care devices. Furthermore, growing awareness about home diagnostic devices is estimated to spur the growth of the segment.

Regional Insights

North America was at the forefront of the global market, with a share of a little over 40.0% in 2017. This can be attributed to high adoption of technologically advanced products, product launches, and government initiatives. For example, in September 2017, Philips launched new ultrasound innovative products, Philips EPIQ 7, EPIQ 5, and Affiniti 70 ultrasound systems, to ensure easier, earlier, and more reliable diagnosis. This launch is likely to help expand its foothold in this region. In the U.S., Home Access Health introduced a home testing kit, which can be used to obtain a sample and send it to a laboratory for testing for fast and effective diagnosis.

Asia Pacific is projected to be the fastest-growing region during the forecast period. Improving healthcare infrastructure, rising awareness about women’s health disorders, government initiatives, and increased participation of women in workforce are some of the factors poised to positively influence the growth of the regional market.

Women’s health diagnostics market

In November 2016, the Indian government launched Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) scheme to provide free health checkups to pregnant women. Under this scheme, women would be tested for anemia, high blood sugar (gestational diabetes), blood pressure, hormonal disorders, and have access to free ultrasounds to track health and development of baby in the womb.

Brazil and Mexico are important markets in Latin America, with the former being the leading revenue contributor in the region. Declining maternal mortality rate, increasing life expectancy, aging women population, and growing prevalence of infectious & chronic diseases are primary growth stimulants for the regional market. In 2015, Brazil started distributing self-testing kits to general population. These kits were obtained free of charge from medication distribution centers, pharmacies, government health programs, health services, and through mails.

Women’s Health Diagnostics Market Share Insights

Competitive rivalry is high owing to existence of various players. Some of the major players are Siemens Healthcare Private Limited; Hologic, Inc.; GE Healthcare; F. Hoffmann-La Roche Ltd.; bioMérieux SA; Koninklijke Philips N.V.; Abbott; and BD.

Mergers & acquisitions, partnerships, and expansion of regional presence are among key strategies employed by market players to remain competitive. For instance, in September 2017, Quest Diagnostics acquired two hospitals of Hartford HealthCare (HHC), namely Hospital of Central Connecticut and William W. Backus Hospital to enhance its lab services. In June 2013, Hologic, Inc. entered into a strategic alliance with Quest Diagnostics to expand its product portfolio in the diagnostics segment of Aptima products for women’s health.

Furthermore, in September 2016, GE Healthcare entered into a partnership with Trice Imaging, Inc. for Tricefy, a cloud-based image sharing solution. This partnership enhanced its ultrasound women’s health product portfolio.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2018 - 2025

Market representation                         

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Country scope

U.S., Canada, U.K., Germany, Japan, China, Brazil, Mexico, & South Africa

Report coverage  

Revenue forecast, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of industry trends in each of the sub segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global women’s health diagnostics market report on the basis of application, end use, and region:

  • Application Outlook (Revenue, USD Million, 2014 - 2025)

    • Cancer

      • Breast Cancer Testing

      • Cervical Cancer Testing

      • Ovarian Cancer Testing

    • Infectious Disease Testing

    • Osteoporosis Testing

    • Pregnancy and Fertility Testing

    • Prenatal Testing

  • End Use Outlook (Revenue, USD Million, 2014 - 2025)

    • Hospital and Diagnostics Centers

    • Home

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon